Analyst Price Targets — RPD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 12:51 pm | — | RBC Capital | $11.00 | $12.31 | TheFly | Rapid7 price target raised to $11 from $6 at RBC Capital |
| July 15, 2026 10:50 am | — | Mizuho Securities | $11.00 | $12.97 | TheFly | Rapid7 price target raised to $11 from $8 at Mizuho |
| May 7, 2026 9:38 am | — | Barclays | $6.50 | $6.57 | TheFly | Rapid7 price target lowered to $6.50 from $8 at Barclays |
| May 6, 2026 1:19 pm | — | Raymond James | $8.00 | $6.74 | TheFly | Rapid7 price target lowered to $8 from $15 at Raymond James |
| May 6, 2026 11:32 am | — | Piper Sandler | $8.00 | $6.68 | TheFly | Rapid7 price target lowered to $8 from $10 at Piper Sandler |
| May 6, 2026 11:27 am | Patrick Colville | Scotiabank | $7.00 | $6.68 | TheFly | Rapid7 price target lowered to $7 from $9 at Scotiabank |
| May 6, 2026 11:24 am | — | Robert W. Baird | $8.00 | $6.68 | TheFly | Rapid7 price target lowered to $8 from $11 at Baird |
| May 6, 2026 11:20 am | Adam Borg | Stifel Nicolaus | $7.00 | $6.68 | TheFly | Rapid7 price target lowered to $7 from $9 at Stifel |
| May 6, 2026 10:27 am | Meta Marshall | Morgan Stanley | $9.00 | $6.68 | TheFly | Rapid7 price target lowered to $9 from $10 at Morgan Stanley |
| April 24, 2026 1:25 pm | Junaid Siddiqui | Truist Financial | $6.00 | $5.92 | TheFly | Rapid7 price target lowered to $6 from $8 at Truist |
Latest News for RPD
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will release its second quarter 2026 financial results on Monday, August 10, 2026, after the financial markets close. The company will host a conference call that same day to discuss its results and business outlook at 4:30 p.m.
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia…
Rapid7 (RPD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CHICAGO--(BUSINESS WIRE)--Reveal, the provider of integrated AI-native platforms that span the eDiscovery lifecycle, today announced a major expansion of its European operations, bringing Reveal Private Deployment (RPD), its aji GenAI review engine and Logikcull's government transparency capabilities to organizations across EMEA. The expansion addresses the unique data sovereignty, regulatory compliance and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RPD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.